

Introduction

Worldwide, cervical cancer (CC) was the most common gynecological malignancy and remains one of the leading causes of cancer death among women, in 2020.

GRELI

Cancer screening programs allows its early detection, more effective treatments and better overall survival (OS). Presently, CC screening in the Autonomous Region of Madeira (RAM) is opportunistic.

Recommended treatment includes exclusive (CRT), chemoradiotherapy CRT and brachytherapy (BT), or radiotherapy-alone (RT), and surgery followed by adjuvancy.

Objetives

The aim of this study was a demographic and characterization of the population clinical diagnosed with CC between 2011 and 2020 in RAM and the outcomes of the treatments (2009-2020) in locally advanced disease (LAD), according to the FIGO classification by the National Consensus 2020.

Methods

CC cases were obtained from the National Cancer Registry (RON) database platform.

Kaplan-Meier method was used for OS and disease free-survival (DFS). Log-rank test was used for groups comparison).

Conclusion

Incidence had variations over the last decade in the RAM. Although, in 2020, the world standardized incidence rate (ASR) of CC in RAM (3.64) was lower compared to the incidence rate verified in Southern Europe (7.7) and worldwide (13.3), the number of metastatic and LAD is still high. We found that DFS and OS are higher in patients with CC undergoing multimodal treatment with CRT and BT compared to patients who only underwent CRT, accordingly to bibliography.

References

- 1. Bhatla N, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):28-44. doi: 10.1002/ijgo.13865.
- 2. Bentahila R, et al. Providing Patients with Locally Advanced Cervical Cancer Access to Brachytherapy: Experience from a Referral Network for Women Treated in Overseas France. Cancers (Basel). 2022 Jun 14;14(12):2935. doi: 10.3390/cancers14122935.
- Mayadev JS, et al. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. Int J Gynecol Cancer. 2022 Mar;32(3):436-445. doi: 10.1136/ijgc-2021-003001.
- 4. Sung, Hyuna, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 71.3 (2021): 209-249. doi: 10.3322/caac.21660.

Results

For the epidemiological study it were considered 125 cases with diagnosis between 2011-2020. CC was the 3rd most incident gynecological cancer in RAM, preceded by corpus uteri and ovarian cancers. The tumors were squamous cells (72%), adenocarcinoma (20%) and unspecified morphology (8%).









² Clínica de Radioncologia da Madeira, Joaquim Chaves Saúde, Rua de Santa Rita nº17, 9000-772 Funchal, Portugal

For treatment study it were considered 148 new cases of CC diagnosed between 2009 and 2020, with a median age of 54 years (IQR=68-45). 45 cases were diagnosed as local disease, 82 as LAD and 17 cases as metastatic disease.

Stage at diagnosis

Description n n Trail 448 Age (vars, mellan) 54 (6-54) Total LAD 59 (564) Total LAD 59 (564) Bage group FIGO (n-14) Local 93.1% 660.% 80.2% 45 (2 /4) Local 93.1% 660.% 80.2% 45 (2 /4) Local 93.1% 660.% 80.2% 45 (2 /4) Metastatic 28.4% 22.1% 14.7% 17 (14) Metastatic 28.4% 52 (14) Metastatic 28.4% 52.1% 14.7% 17 (14) Metastatic 28.4% 18 (14) An or evidence of disease and 17.4% had local or/ and distant recurrence. In patients with LAD, 5-year OS was 56.3% (67 CKT) p=014). Complete response S8 (0,7.4%) Metastatic 28.4% 17 (14) Metastatic 28.5% 17.5% 17 (14) Metastatic 28.5% 17.5% 17 (14) Metastatic 28.5% 17.5% 17 (14) Metastatic 28.5% 17.5% 17 (15) Metastatic 28.5% 17.5% 17 (16) Metastatic 28.5% 17.5% 17 (16) Metastati	Characterization of the CC population (2009-2020)			Survival rate by stage												++-+-1++	[
Total LAR OS Typed 3 yours 5 yours (ataths) value Ace (years, median) 52 (55 45) Sigg and genosis 54 (46-8) Local y advanced 87.5% 65.2% 65.3% 62.1% 65.3% 62.1% 45 (7) -0	Description	n	Survival rate(%) n P							0.8-		5-3 ₋		Loc	al		
Age (vers, median) 54 (45 68) Stage group FIGO (m=14) Stage group FIGO (m=14) Stage group FIGO (m=14) Stage at diagnosis St	Total	148		OS	·	1 vear 3	8 vears	5 vears (deaths)	valu	م 9				+~~~	·+	-
Total LOD 82 (55 4%) Decal 93 (% 86 0% 83 0% 45 (?) Coll Col	Age (years, median)	54 (45-68)	Stage	aroup	FIGO (n=148)	, , , , , , , , , ,	- , [urviv —	0.6	Unk	nown		++++++ Locally advar	
Ape (pars, median) 56 (46 6.5) Stage at diagnosis (11) 183 3 (3.7%) 184 3 (3.7%) 183 3 (3.7%) 184 5 (6.1%) 186 8 (3.87%) 188 8 (3.87%) 188 8 (3.87%) 188 8 (3.87%) 188 8 (3.87%) 188 8 (3.87%) 188 8 (3.87%) 188 8 (3.87%) 189 3 (3.87%) 180 8 (3.87%) 181 12 (3.7%) 182 3 (3.7%) 183 3 (3.6.6%) 184 5 (6.3%) 183 3 (3.2%) 184 3 (3.7%) 183 3 (3.2%) 184 3 (3.7%) 184 3 (3.7%) 184 3 (3.7%) 184 3 (3.7%) 184 3 (3.7%) 184 3 (3.7%) 184 3 (3.7%) 184 3 (3.7%) 188 3 (3.7%)	Total LAD	82 (55.4%)	Jugo	Local		93.1%	86.0%	83.0%	45 (7)		s mu	0.4-					
Stoge at diagnosis (374) 183 3 (374) 184 3 (374) 183 3 (174) 184 3 (174) 184 3 (174) 184 3 (174) 184 3 (174) 184 3 (174) 186 3 (174) 188 4 (174) 188 4 (174) 189 3 (174) 188 4 (174) 189 3 (174) 180 4 (174) 181 3 (174) 183 10 (174) 183 10 (174) 183 10 (174) 183 10 (174) 10 (174) 183 10 (174) 10 (174) 184 10 (174) 10 (174) 10 (174) 184 10 (174) 10 (174) 10 (174) 184 10 (174) 10 (174) 10 (174) 10 (174) 184 10 (174) 10 (174) 10 (174) 10 (174) 10 (174) 184 10 (174) 10 (174) 10 (174) 10	Age (years, median)	56 (46-68)	Local	lv adva	nced 8	37.8%	65.2%	56.3%	82 (34)	<.01	0	0.4					
IB3 3 (3.7%) IIA2 3 (3.7%) IIB 3 7 (45.1%) IIB 3 (6.4%) IIIC 17 (20.7%) IIIC 17 (20.7%) 100 (5 (30) 00 (6 (30)) 00 (6 (30)) 00 (7 (7 (7 (7 (7 (7 (7 (7 (7 (7 (7 (7 (7	Stage at diagnosis		Me	etastat	ic 2	29.4%	22.1%	14.7%	17 (14)			0.2-				+	
HA2 316.7%1 Matrix	IB3	3 (3.7%)										0.2					+
IIB 37 (45 1%) IIIA 5 (6 3%) IIIB 6 (9 5%) IIIA 6 (9 5%) IIIA 9 (13%) IIIC 17 (20 7%) IIIC 17 (20 7%) 17 (20 7%) IIIC 17 (20 7%) 17 (20 7%) 17 (20 7%) IIIC 17 (20 7%) 17 (20 7%) 17 (20 7%) 17 (20 7%) Adjuvant CR1 + 8T 2 (2 4%) 18 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 - 20 7%) 10 (2 -	IIA2	3 (3.7%)										0.0-				Metast	atic
InA 5 (6.3%) Regarding LAD, 39% underwent CRT and BT, and 36.6% CRT alone. 70.7% had complete response IRC 17 (20.7%) Regarding LAD, 39% underwent CRT and BT, and 36.6% CRT alone. 70.7% had complete response CRT 30 (36.6%) RT alone 4 (4.9%) Adjuvant CRT 2 (24%) Other Other Other Other Other Other Other Poll4! Image: Presidence Pices	IIB	37 (45.1%)											.0 1	1.0 2		0 4.0	 5.0
IIIE 8 (9.8) Regarding LAD, 39% underwent CRT and BT, and 36.5% CRT alone. 70.7% had complete response and 25% had tumor persistence. At 60 months of follow-up 52.4% still had no evidence of disease and 17.4% had local or/and local or/and local bistant recurrence. Regarding LAD, 39% underwent CRT and BT, and 36.5% CRT alone. 70.7% had complete response and 25% had tumor persistence. At 60 months of follow-up 52.4% still had no evidence of disease and 17.4% had local or/and	IIIA	5 (6.1%)															0.0
IIC17 (20.7%) (VA9 (1%)IVA9 (1%)IVA9 (1%)IVA9 (1%)IVA9 (1%)CRT + 8T22 (3%)CRT30 (36.6%)Adjuvant (CT + 8T5 (6.3%)Adjuvant (CT + 8T5 (6.3%)Adjuvant (CT + 75 (6.3%)Adjuvant (CT + 75 (6.3%)CRT and BT, and SA.5% for CRT, p>.0S) and DFS was 51.9% (64.4% for CRT and BT and 36.8% for CRTAdjuvant (CT + 8T5 (6.3%)Adjuvant (CT + 6T)5 (6.3%)Complete response55 (70.7%)Status after treatment(1.2%)Complete response55 (70.7%)Discase free source9 (1%)ILCal and distant recurrence9 (1%)ILCal and distant recurrence9 (1%)ILCal and distant recurrence9 (1%)Local arcd distant recurrence3 (3.7%)Unknown1 (1.2%)Curuulative risk 0-74 years2.00ILCal and distant recurrence3 (3.7%)Distant scurrence9 (1%)Local arcd distant recurrence3 (3.7%)Unknown1 (1.2%)ILCal and distant recurrence9 (1%)Local arcd distant recurrence3 (3.7%)Local arcd distant recurrence9 (1%)Local arcd distant recurrence	IIIB	8 (9.8%)	Rega	rding		9% un	derwer	nt CRT a	nd BT	and 3	6 6% (CRT	alone 7	70 7% h	ad com	nnlete respo	onse
VA 9 (11%) Treatment CRT + 8T 2 (39%) CRT 30 (36 68%) Adjuvant CRT 2 (24%) Overall survival Discusse free-survival Other 6 (7.3%) Nume 9 (11%) Status after treatment 3 (37%) 1 (24%) Nume 9 (11%) Status after treatment 3 (37%) 1 (24%) Nume 1 (24%) Nume 1 (24%) Other 6 (7.3%) Its 1 (24%) Nume 3 (0) Nume 1 (24%) Nume 1 (24%) Nume 1 (24%) Nume 1 (24%) Nume Num Nume Nume <	IIIC	17 (20.7%)	and	78% h	ad tun	nor ner	rsistenc	$re \Delta t 60$	month	ns of f		un 5	2 4% st	ill had	no evid	ence of disc	
Treatment CRT and 5 J S M Find Michael M (Michael M) (Michae	IVA	9 (11%)	and 1	17 /1%	had lo	cal or/a	and dist	tant roci	irronco	Inna	otionts	with	$1 \wedge D = 5$	-voar O	$S_{\rm Was} = 5$	6 3% (67 3%	6 for
CRT is 10 5 (39%) CRT is 10 5 (31%) Discare (bit A) (0) CRT is 10 5 (41%) (0) CRT is 10 5 (10 C T C T C T C T C T C T C T C T C T C	Treatment			und RT	and I	51 5% f	or CPT	n > 05	and DEG		51 00/	(61	10% for (PT and	J Was J	126.8% for	
CRT 30 (36.6%) p=-114). RT alone 4 (4.9%) 5 (6.1%) Coverall survival Disease free-survival n P Adjuvant CRT 2 (2.4%) (n=82) Verall survival (death) value (n=82) Image: survival (n=82) Image: survival (n=82) Image: survival (n=82)	CRT + BT	32 (39%)		ани рі 1 л \	, anu .	J4.J70 I	UI CNI,	, p>.05)		5 Was	51.570	(04.4	4701010			1 50.070 101	CNI,
Image Image <t< td=""><td>CRT</td><td>30 (36.6%)</td><td>ρ=.0.</td><td>L4).</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	CRT	30 (36.6%)	ρ=.0.	L4).													
Adjuvant CRT + BT 5 (6.1%) $(n=82)$ $DFS(%)$ n p Adjuvant CRT 2.(2.4%) 1 1 $years$ 5 $pears$ 1 <td>RT alone</td> <td>4 (4.9%)</td> <td></td> <td></td> <td>0</td> <td colspan="3">Overall survival</td> <td colspan="3"></td> <td colspan="6">Disease free-survival</td>	RT alone	4 (4.9%)			0	Overall survival						Disease free-survival					
Adjuvant CRT 2 (2,4%) (n=82) $CS (S^{1})$ n p (n=82) $CS (S^{1})$ (n<8) $SS (S^{1})$ $CS (S^{1})$ $CS (S^{1})$ $CS (S^{1})$ $CS (S^{1})$ $SS (S^{1})$ $CS (S^$	Adjuvant CRT + BT	5 (6.1%)				05 (9/)			D	-							
Other 1 year 3 years 5 years (1 year) 3 years <td>Adjuvant CRT</td> <td>2 (2.4%)</td> <td>(n=8</td> <td>32)</td> <td></td> <td>05 (%)</td> <td>n (deathc</td> <td>P N value</td> <td></td> <td>(n=8</td> <td>32)</td> <td></td> <td>DFS(%)</td> <td></td> <td>n (recurrence)</td> <td>p value</td>	Adjuvant CRT	2 (2.4%)	(n=8	32)		05 (%)		n (deathc	P N value		(n=8	32)		DFS(%)		n (recurrence)	p value
Without treatment 3 (3.7%) 3 (3.7%) Status after treatment 100.0% 3 (0) 30.0% <td>Other</td> <td>6 (7.3%)</td> <td></td> <td></td> <td>1 year</td> <td>3 years</td> <td>s 5 year</td> <td>S</td> <td>oj value</td> <td></td> <td></td> <td></td> <td>1 year</td> <td>3 years</td> <td>5 years</td> <td>(recurrence)</td> <td>value</td>	Other	6 (7.3%)			1 year	3 years	s 5 year	S	oj value				1 year	3 years	5 years	(recurrence)	value
Status after treatment IIA2 10.0.0% 33.3% 3.2 3.3.3% 3.2 Complete response 58 (70.7%) 23 (28%) IIA 80.0% 40.0% 5 (3) IIA 80.0% 30.0% 50.0% 31.3% 32.2% 100.0% 33.3% 3 (2) IIA 80.0% 40.0% 5 (3) IIB 97.3% 77.6% 70.6% 37 (10) IIA 80.0% 40.0% 5 (3) IIB 62.5% 37.5% 38 (5) IIB 62.5% 37.5%	Without treatment	3 (3.7%)		IB3	100.0%	100.0%	100.0%	6 3 (0)		-	LAI	D	69.4%	54.9%	51.9%	82 (38)	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Status after treatment			IIA2	100.0%	33.3%	33.3%	3 (2)				IB3	100.0%	100.0%	100.0%	3 (0)	
Tumor persistence 23 (28%) IIIA 80.0% 80.0% 40.0% 5 (3) .058 Unknown 1 (1.2%) IIIA 80.0% 80.0% 40.0% 5 (3) .058 Without disease 43 (52.4%) IIIC 75.5% 77.5% 77.5% 77.5% 77.5% 80.0% 90.0% 90.0% 90.0% 90.0% 90.0% 90.0%	Complete response	58 (70.7%)	Stage (FIGO)	IIR	97 3%	77 6%	70.6%	37 (10)				IIA2	100.0%	33.3%	33.3%	3 (2)	
Unknown 1 (1.2%) IIIA 80.0% 80.0% 90.0% 5 (3) IIIA 80.0% 80.0% 40.0% 5 (3) IIIA 80.0% 40.0% 5 (3) IIIA 80.0% 40.0% 5 (3) IIIA 80.0% 40.0% 5 (4) IIIA 80.0% 60.0% 7 (10) IIIA 80.0%	Tumor persistence	23 (28%)			00.00/	77.070	10.070		.058		Stage	IIB	97.3%	77.6%	70.6%	37 (12)	~ · · ·
Pollow-up (cut-off at 31-08-2022 or 60 months) Without disease 43 (52.4%) Mile 7.5% 37.5% $3(5)$ Uccal recurrence 3 (3.7%) Distant recurrence 9 (11%) Local and distant recurrence 3 (3.7%) 32.2% 41.5% $9 (4)$ OS in LAD by treatment $p=.257$ 0.00 0	Unknown	1 (1.2%)		IIIA	80.0%	80.0%	40.0%	5 (3)			(FIGO)	IIIA	80.0%	80.0%	40.0%	5 (4)	.044
Without disease 43 (52.4%) Local recurrence 3 (3.7%) Distant recurrence 9 (11%) Local and distant recurrence 3 (3.7%) Unknown 1 (1.2%) 0 0 1 0 1 0 0 0 0 1 0	Follow-up (cut-off at 31-08-2022 or 60 months)			IIIB	62.5%	37.5%	37.5%	8 (5)				IIIB	62.5%	37.5%	37.5%	8 (4)	
Local recurrence 3 (3.7%) Distant recurrence 3 (3.7%) Local and distant recurrence 3 (3.7%) Tumor persistence 23 (28%) Unknown 1 (1.2%) $unulative risk 0-74 years$ $2,00$ 1,20 $2,00$ 0,00 0,00 <td>Without disease</td> <td>43 (52,4%)</td> <td></td> <td>IIIC</td> <td>76.5%</td> <td>47.1%</td> <td>40.3%</td> <td>5 17 (10)</td> <td>)</td> <td></td> <td></td> <td>IIIC</td> <td>76.5%</td> <td>47.1%</td> <td>40.3%</td> <td>17 (10)</td> <td></td>	Without disease	43 (52,4%)		IIIC	76.5%	47.1%	40.3%	5 17 (10))			IIIC	76.5%	47.1%	40.3%	17 (10)	
Distant recurrence $9 (13)$ Local and distant recurrence $3 (3.7\%)$ Local and distant recurrence $3 (2.8\%)$ Unknown $1 (1.2\%)$ cumulative risk 0-74 years $2,00$ $1,20$ $\frac{5}{90}$ 0,00 0,0		3 (3 7%)		IVA	88.9%	62.2%	41.5%	9 (4)				IVA	88.9%	62.2%	41.5%	9 (6)	
$ \begin{array}{c} \text{OS in LAD by treatment} \\ \text{OS in LAD by treatment} \\ \text{Cumulative risk 0-74 years} $	Distant recurrence	9 (11%)								-							
$\frac{1}{10000} \frac{1}{10000} \frac{1}{10000} \frac{1}{10000} \frac{1}{10000} \frac{1}{100000} \frac{1}{10000000000000000000000000000000000$	Local and distant recurrence	3 (3 7%)			OS in	LAD by t	reatmen	t					DFS	in LAD by	' treatme	nt	
$\begin{array}{c} 1 \\ 1 \\ 1 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\$	Tumor persistence	23 (28%)	1	.00.				p=.2	257			1.0-				p=.014	
$\begin{array}{c} cumulative risk 0-74 years \\ 2016 \\ 2017 \\ 2018 \\ 2019 \\ 2020 \\ 0,00 \\ 0$	Unknown	1 (1 2%)				[1 ⊢								L			
cumulative risk 0-74 years 2,00 1,20 1,20 1,20 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 1,20 0,40 0,40 1 1 year 3 years 5 years (deaths) value QRT $93.3%$ $59.0%$ $54.5%$ $30(13)QRT$ $56.3%$ $36.8%$ $36.8%$ $30.8%$ $30(18)$		1 (1.270)	C).8-			۲ <u>. </u>	QRT+E	зт			0.8-			1	ORT+BT	
cumulative risk 0-74 years 2,00 1,20 1,20 1,20 1,20 1,20 1,20 0,30 1,20 1,20 0,40 0,40 0,40 0,40 0,40 0,201 2013 2017 2018 2017 2018 2019 2020 0,00			a			L	<u> </u>	·+	+				L		L		
cumulative risk 0-74 years $ \begin{array}{c} $			Surviv						-+ 		Surviv	0.6		+ ₁			
$\sum_{2016} 2017 2018 2019 2020 \\ Cumulative rick (1000000) \\ Cumulative rick (1000000)$	cumulative risk 0-74 years		Cum).4-				QK			Cum	0.4-		L+	۲	QRT	
$ \begin{array}{c} 1,60 \\ 1,20 \\ 1,20 \\ 0,80 \\ 0,80 \\ 0,80 \\ 0,00 \\ 0$		┌ 2,00															
$\begin{array}{c} \begin{array}{c} 1, 00 & \frac{1}{2} \\ 1, 20 & \frac{1}{2} \\ 0, 80 & \frac{1}{2} \\ $		1 60 50	C).2-								0.2-					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		- 1,00 % 															
OS (%) n P 2016 2017 2018 2019 2020 0,00 0		- 1,20 ·= y			1.0	2.0	3.0	4.0] 5.0			0.0 L	0 1.0	2.0	3.0	4.0 5.0	
2016 2017 2018 2019 2020 0,00 0,00 1 year 3 years 5 years (deaths) value 0,00 1 year 3 years 5 years (deaths) value 0,00 1 year 3 years 5 years (deaths) value 0,00 1 year 3 years 5 years (deaths) value 0,00 1 year 3 years 5 years (deaths) value 0,00		- 0,80 -															
Image: construction of the state of the			(C)S (%)		n	Р		(D	FS (%)		n	р
2016 2017 2018 2019 2020 QRT+BT 96.9% 77.6% 67.3% 32(10) .257 QRT+BT 90.6% 71.2% 64.4% 32 (11) .0 Cumulative risk Linear (Incidence rate (/100000)) QRT 93.3% 59.0% 54.5% 30(13) QRT 56.3% 36.8% 36.8% 30 (18) .0			(n=62)	1 ye	ear 3	years	5 years	(deaths	s) value)	(11=02)	1	1 year 🔅	3 years	5 years	(recurrence)	value
QRT 93.3% 59.0% 54.5% 30(13) QRT 56.3% 36.8% 36.8% 30(18)	2016 2017 2018 2010 2020	⊥ 0,00	QRT+B	F 96.9	9% 7	7.6%	67.3%	32(10)	.257	C	QRT+B	Γ	90.6%	71.2%	64.4%	32 (11)	.014
	$\sum_{i=1}^{2} \sum_{j=1}^{2} \sum_{i=1}^{2} \sum_{i=1}^{2} \sum_{i=1}^{2} \sum_{i=1}^{2} \sum_{i$		QRT	93.3	3% 5	9.0%	54.5%	30(13)			QRT	5	56.3%	36.8%	36.8%	30 (18)	

Incidence rate, ASR World and



